Marks J G, Trautlein J J, Epstein W L, Laws D M, Sicard G R
Arch Dermatol. 1987 Apr;123(4):476-8.
We evaluated the safety and efficacy of a 1:1 mixture of pentadecylcatechol (PDC) and heptadecylcatechol (HDC) diacetate in reducing hypersensitivity to poison ivy and poison oak. The study was double-blind, parallel, randomized, and placebo controlled. The 44 subjects receiving the active drug ingested a cumulative dose of 306.5 mg over a five-week period. Subsequently, 14 patients were continued on a maintenance phase, ingesting an additional 960 mg of drug. The PDC-HDC diacetate was well tolerated, with no significant side effects. Evaluation of efficacy compared poststudy and prestudy reactions to patch tests using urushiol in doses of 0.025, 0.05, 0.125, 0.25, and 0.5 micrograms applied to the forearm. The results indicated that the induction phase as well as the maintenance phase did not induce a statistically significant hyposensitivity to urushiol, and we were thus unable to decrease sensitivity to poison ivy and poison oak in humans using orally ingested PDC-HDC diacetate.
我们评估了十五烷基儿茶酚（PDC）和十七烷基儿茶酚（HDC）二乙酸酯1:1混合物在减轻对毒葛和毒栎过敏反应方面的安全性和有效性。该研究为双盲、平行、随机且安慰剂对照试验。44名接受活性药物的受试者在五周内累计摄入剂量为306.5毫克。随后，14名患者进入维持阶段，额外摄入960毫克药物。PDC - HDC二乙酸酯耐受性良好，无明显副作用。通过对前臂分别涂抹剂量为0.025、0.05、0.125、0.25和0.5微克漆酚进行斑贴试验，比较研究后和研究前的反应来评估疗效。结果表明，诱导期和维持期均未对漆酚产生统计学上显著的低敏反应，因此我们无法通过口服PDC - HDC二乙酸酯降低人类对毒葛和毒栎的敏感性。
